Authors
Latest:
BMS-986279 Shows Promise in Noninvasive fuc-GM1 Detection for ES-SCLCZirconium-89–labeled BMS-986279 demonstrated tumor uptake in fuc-GM1–positive lesions in patients with ES-SCLC.
Latest:
Opinion: Increasing Support and Awareness for AYAs With CancerAYA Cancer Awareness Month offers an opportunity for nurses to go further in supporting AYAs with cancer.
Latest:
Advancing CML Management Towards an Ideal Patient JourneyThe panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
Latest:
Key Takeaways for Patients With MyelofibrosisPatients with myelofibrosis should reflect on their personal priorities and quality of life goals, understand the range of available JAK inhibitor treatment options, and openly communicate with their doctor to arrive at a shared decision for managing their disease.
Latest:
Colorectal Cancer Screening: Education, Advocacy, and ActionIt is essential to continue to develop and incorporate educational strategies to increase screening for colorectal cancer in our communities.
Latest:
Discrepancies Exist Between Actual Care and Trial-Based Recommendations in MCLDiscrepancies exist between actual patterns of care and recommendations based on clinical trials in adult patients with mantle cell lymphoma.
Latest:
Nivolumab/Ipilimumab to Be New MSI-H/dMMR mCRC Standard of CareLasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients with MSI-H/ dMMR metastatic colorectal cancer.
Latest:
Oncology Drug Crash Course: Tucatinib and Trastuzumab for HER2+ CRCTucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.
Latest:
Managing Early HER2+ mBC: Patient-Centered Approaches and Evolving Treatment StrategiesExperts discuss how, it is crucial to approach treatment strategies with both compassion and transparency. It is important to explain the complexity of the situation and maintain clear and accessible language when discussing treatment strategies with patients and their families.
Latest:
T-Cell Engagers Take Center Stage in Large B-Cell LymphomaBispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.
Latest:
Opinion: Now Is the Time to Optimize Electronic Health Record SystemsBuying one for your practice or enhancing the one you have will help you cut costs and boost your financial stability.
Latest:
Closing Reflection: A Journey of Understanding and ResiliencePanelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease management and improve quality of life while identifying opportunities to strengthen provider communication and access to resources.
Latest:
Kristin Daly on the Difference Between Somatic and Germline Variants in Precision OncologyKristin M. Daly, MSN, ANP-BC, AOCNP, highlights the difference between somatic and germline variants.
Latest:
Cleveland Clinic Opens New Cancer Center in Abu DhabiThe state-of-the-art facility represents the organization’s vision of global cancer care
Latest:
Oncology Drug Crash Course: Pirtobrutinib (Jaypirca)Sharon Kauffman, PhD, RN, CNE, NPD-BC, OCN, provides an in-depth look at pirtobrutinib in a downloadable reference sheet.
Latest:
Innovative Program Reduces Nurse Turnover and Fosters DevelopmentThe US Oncology Network (The Network) has developed one of the most comprehensive programs in the nation to support the professional development and retention of new oncology nurses.
Latest:
COVID-19 and the Rise of Texting in Health CareThe last thing patients want is to be put on hold or interrupted by calls at work.
Latest:
The Treatment Landscape For Advanced EGFR-Mutant NSCLCPanelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer (NSCLC) has evolved to include 3 viable frontline options (osimertinib alone, osimertinib plus chemotherapy, and amivantamab plus lazertinib), with treatment selection based on patient characteristics, preferences, and physician judgment rather than a strict algorithmic approach.
Latest:
How Social Media Helps AYA Patients With Cancer Find SupportThe rise of social media platforms has helped foster a community for adolescent and young adult patients with cancer.
Latest:
Informing Patients With Cancer About the Potential Impact of Immunotherapy on PregnancyAn expert explores the complexities of immunotherapy during pregnancy, highlighting risks to the fetus and the crucial role of oncology nurses in patient education and management.
Latest:
Kara Morris and Christine Wylie on Oral Cryotherapy for Chemotherapy-Induced Mucositis in Breast CancerKara Morris, MSN, RN, OCN; and Christine Wylie, MSN, RN, OCN, discuss the benefits of oral cryotherapy for patients receiving dose-dense doxorubicin.
Latest:
Anemia Protocol Does Not Reduce Ruxolitinib Efficacy in MyelofibrosisAdding danazol or erythropoiesis-stimulating agents for anemia management to a ruxolitinib regimen for myelofibrosis does not decrease treatment efficacy.
Latest:
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian CancerIn addition to a significant PFS benefit vs nab-paclitaxel alone, the combination provides an at-home option for patients with ovarian cancer.
Latest:
Improved PFS Outcomes With Elacestrant Correlate With CDK4/6 Duration in ER+/HER2– Metastatic Breast CancerLonger duration of CDK4/6 inhibitor prior to treatment with elacestrant correlated with progression-free survival (PFS) improvements in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer vs standard-of-care options.
Latest:
Patient Education Is Key to Improve Patient Adherence to Cancer TreatmentJessie Desir, PhD, RN, AMB-BC, OCN, explained that comprehensive disease and treatment education are essential to adherence for patients with breast cancer.
Latest:
Meredith Cummings on Using Machine Learning to Predict Treatment-Related Adverse EventsMeredith Cummings BSN, RN, OCN, highlights her research on machine learning and its potential application in optimizing symptom management.
Latest:
Newly Approved Tebentafusp Requires Up-Front Active Toxicity Management in MelanomaTebentafusp, the first FDA-approved treatment option for patients with unresectable or metastatic uveal melanoma, may cause mild cytokine release syndrome, an expert explains.
Latest:
Cardiotoxicities in Oncology Necessitate Nurse VigilanceThe intersection of cardiology and oncology is greater than nurses and providers may assume, explained 2 experts.
Latest:
Eric Zack on Disseminated Intravascular Coagulation Prevention and ManagementEric Zack, DNP, RN, ACNP-BC, AOCN, BMTCN, describes disseminated intravascular coagulation and best nursing strategies to mitigate the severity of this condition.
Latest:
Hospice Professionals Use Mind, Body, and Movement Meditation to Reduce StressA program evaluated at Michigan State University has shown that meditation helps combat burnout and promote well-being among health care workers, particularly in hospice settings.
